CA2818593A1 - Biomarqueurs pronostiques chez des patientes atteintes d'un cancer ovarien - Google Patents

Biomarqueurs pronostiques chez des patientes atteintes d'un cancer ovarien Download PDF

Info

Publication number
CA2818593A1
CA2818593A1 CA2818593A CA2818593A CA2818593A1 CA 2818593 A1 CA2818593 A1 CA 2818593A1 CA 2818593 A CA2818593 A CA 2818593A CA 2818593 A CA2818593 A CA 2818593A CA 2818593 A1 CA2818593 A1 CA 2818593A1
Authority
CA
Canada
Prior art keywords
biomarkers
ovarian cancer
subject
sample
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2818593A
Other languages
English (en)
Inventor
Estrid Hogdall
Eric T. Fung
Ib Jarle Christensen
Claus Hogdall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspira Womens Health Inc
Original Assignee
Vermillion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vermillion Inc filed Critical Vermillion Inc
Publication of CA2818593A1 publication Critical patent/CA2818593A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44773—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis
    • G01N27/44778—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis on a common gel carrier, i.e. 2D gel electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2818593A 2010-10-22 2011-10-21 Biomarqueurs pronostiques chez des patientes atteintes d'un cancer ovarien Abandoned CA2818593A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40604410P 2010-10-22 2010-10-22
US61/406,044 2010-10-22
PCT/US2011/057271 WO2012054824A2 (fr) 2010-10-22 2011-10-21 Biomarqueurs pronostiques chez des patientes atteintes d'un cancer ovarien

Publications (1)

Publication Number Publication Date
CA2818593A1 true CA2818593A1 (fr) 2012-04-26

Family

ID=45975910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2818593A Abandoned CA2818593A1 (fr) 2010-10-22 2011-10-21 Biomarqueurs pronostiques chez des patientes atteintes d'un cancer ovarien

Country Status (5)

Country Link
EP (1) EP2630498A4 (fr)
JP (2) JP2013541716A (fr)
AU (1) AU2011316844A1 (fr)
CA (1) CA2818593A1 (fr)
WO (1) WO2012054824A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914918C (fr) * 2013-05-10 2023-10-10 Johns Hopkins University Compositions et methodes d'evaluation du cancer de l'ovaire a specificite amelioree
US10324084B2 (en) 2014-04-23 2019-06-18 Nichirei Biosciences Inc. Combination product for detecting target marker
EP3435379A1 (fr) * 2017-07-27 2019-01-30 Roche Diagnostics GmbH Augmentation des valeurs de mesure d'échantillons biologiques
WO2019088709A2 (fr) * 2017-10-31 2019-05-09 국립암센터 Procédé de fourniture d'informations pour la prédiction d'un pronostic pour le cancer de l'ovaire utilisant le gène nc886
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1540010T3 (da) * 2002-08-06 2010-07-26 Univ Johns Hopkins Anvendelse af biomarkører til påvisning af ovariecancer
EP2199801B1 (fr) * 2004-07-14 2013-05-29 The Regents of The University of California Biomarqueurs pour la détection précoce du cancer des ovaires
CA2602088C (fr) * 2005-03-11 2021-07-27 Ciphergen Biosystems, Inc. Marqueurs biologiques du cancer de l'ovaire et du cancer de l'endometre
US20100197561A1 (en) * 2005-06-24 2010-08-05 Ciphergen Biosystems, Inc. Biomarkers for Ovarian Cancer: B2 Microglobulin
WO2008060376A2 (fr) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithmes pour modèles multivariants pour combiner un panel de biomarqueurs afin d'évaluer le risque de développer un cancer ovarien
WO2008048508A2 (fr) * 2006-10-13 2008-04-24 Vermillion, Inc. Biomarqueurs pronostiques chez des patientes souffrant d'un cancer des ovaires
US8664358B2 (en) * 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
JP5391400B2 (ja) * 2007-10-01 2014-01-15 公益財団法人ヒューマンサイエンス振興財団 α−アクチニン−４遺伝子のコピー数または発現レベルを指標とした膵癌の検出を補助する方法および診断のためのキット
EP2220506B1 (fr) * 2007-10-29 2013-10-02 Vermillion, Inc. Biomarqueurs permettant la détection du cancer des ovaires à un stade précoce
EP2396657B1 (fr) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 comme marqueur pour le pronostic du mélanome malin

Also Published As

Publication number Publication date
EP2630498A2 (fr) 2013-08-28
EP2630498A4 (fr) 2014-10-01
WO2012054824A3 (fr) 2012-07-19
WO2012054824A2 (fr) 2012-04-26
JP2016212116A (ja) 2016-12-15
JP2013541716A (ja) 2013-11-14
AU2011316844A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
KR101107765B1 (ko) 난소암의 검출을 위한 생물 마커의 용도
US8682591B2 (en) Biomarkers for ovarian cancer
US20170089906A1 (en) Biomarkers for ovarian cancer
US20100055690A1 (en) Prognostic biomarkers in patients with ovarian cancer
US20100197561A1 (en) Biomarkers for Ovarian Cancer: B2 Microglobulin
US20090142332A1 (en) Identification of Biomarkers by Serum Protein Profiling
US20140038837A1 (en) Biomarkers for the detection of early stage ovarian cancer
JP2016212116A (ja) 卵巣癌の患者における予後予測バイオマーカー
US20100068818A1 (en) Algorithms for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2014182896A1 (fr) Compositions présentant une grande spécificité pour l'évaluation du cancer de l'ovaire
AU2008236810A1 (en) Biomarkers for ovarian cancer
WO2007133957A1 (fr) Biomarqueurs de mésothéliomes: apoc1 et apoa2
US20150126384A1 (en) Prognostic Biomarkers in Patients with Ovarian Cancer
US20210215701A1 (en) Compositions for ovarian cancer assessment
WO2006071843A2 (fr) Biomarqueurs destines au cancer du sein
US20150153348A1 (en) BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160927

FZDE Discontinued

Effective date: 20190801